Pro 2013-001 (Announcement on Resolution of 8th Board of Directors of Jianfeng Group)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2013-001
Zhejiang Jianfeng Group Co., Ltd.
Resolution Announcement of the 8th Meeting of the 8th Board of Directors
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
On December 20, 2012, Zhejiang Jianfeng Group Co., Ltd. issued a notice to convene the eighth meeting of the eighth board of directors by fax, e-mail, telephone, and personal delivery. On December 31, 2012, the meeting was held as scheduled by means of communication. The company currently has nine directors, and nine directors participating in the voting , comply with the provisions of the "Company Law" and the "Articles of Association", and the resolutions made are legal and valid. The meeting passed the following resolutions:
1. the "Proposal on the Company's Compliance with the Conditions for Issuing Corporate Bonds"
According to the "the People's Republic of China Company Law", "the People's Republic of China Securities Law", "Corporate Bond Issuance Pilot Measures" And other relevant regulations, in accordance with the conditions for listed companies to issue corporate bonds, the company meets the conditions and requirements stipulated by the current policies and laws and regulations for issuing corporate bonds, eligible to issue corporate bonds.
Voting result :__9__ votes yes, __0__ votes no, __0__ votes abstaining.
This proposal shall be submitted to the general meeting of shareholders of the company for deliberation and voting.
2. "Proposal on Issuing Corporate Bonds";
Meeting deliberated and approved item by item: 1 , issuance scale ; 2 , allotment arrangement to the original shareholders of the company ; 3 , bond term ; 4 , bond interest rate and determination method ; 5 , issuance method ; 6 , issuance object ; 7 , guarantee arrangement; 8 , use of raised funds ; 9 , listing of issued bonds ; 10 , Effective date of resolution . For details, please refer to the "Announcement on the Issuance of Corporate Bonds" published on the same day. At the meeting of
, there were 82 votes , results were all :__9__ votes in favor, __0__ votes against, and __0__ votes abstained.
The above proposals still need to be submitted to the general meeting of shareholders for deliberation and submitted to the China Securities Regulatory Commission for approval.3. "Proposal on requesting the company's general meeting of shareholders to authorize the board of directors
and its authorized person to handle matters related to the issuance of corporate bonds"
According to the company's current corporate bond issuance and listing Arrangements, in order to complete the relevant work of this corporate bond legally, efficiently and orderly, in accordance with the "the People's Republic of China Company Law", "the People's Republic of China Securities Law", "Corporate Bond Issuance Pilot Measures" and other laws and regulations and the relevant provisions of the "Articles of Association of Zhejiang Jianfeng Group Co., Ltd.", the company's board of directors intends to request the company's general meeting of shareholders to authorize the board of directors to handle All matters related to the issuance of corporate bonds, the specific content includes but is not limited to:
1, within the scope permitted by laws and regulations, according to the specific conditions of the company and the market, formulate the specific issuance plan of this issue of corporate bonds and revise and adjust the issuance terms of this issue of corporate bonds, including but not limited to the specific issuance scale, bond term, bond interest rate and determination method, issuance timing, whether to issue in installments and the number of issues and the issuance scale of each issue, online and offline issuance ratio, whether to design the resale clause and redemption clause, whether to provide guarantee and guarantee method, the time limit and method of repayment of principal and interest, whether to allocate to shareholders and the specific arrangement of placing to shareholders, listing place and decision to raise funds the specific use of all matters relating to the issuance of the Company's bonds;
2, decide and hire intermediaries to participate in this corporate bond issuance;
3, select bond trustee, sign "bond trustee management agreement" and formulate "bondholder meeting rules";
4, handle the declaration of this corporate bond issuance, and after the completion of this issuance, to handle the listing of the bonds issued, including but not limited to formulation, approval, authorization, signing, execution, modification and completion of all necessary documents related to the issuance and listing of corporate bonds, contract / agreement, contract ( includes but not limited to prospectus, sponsorship agreement, underwriting agreement, bond trusteeship agreement, listing agreement, various announcements and other legal documents ) and appropriate information disclosure in accordance with laws, regulations and other regulatory documents;
5, request the general meeting of shareholders to authorize the board of directors to decide the amount of funds raised to repay company debt and supplement working capital according to the company's financial situation.
6. If the regulatory authority's policy on the issuance of corporate bonds changes or market conditions change, except for matters involving relevant laws, regulations and the company's articles of association that must be re-voted by the general meeting of shareholders, Authorize the board of directors to make corresponding adjustments to the specific corporate bond issuance plan and other related matters based on the new policies and opinions of the regulatory authority or new market conditions;
7. When the market environment or policies and regulations undergo major changes, the board of directors is authorized to decide whether to continue the corporate bond issuance based on the actual situation.
8, handle all other necessary matters related to the issuance of corporate bonds and listing.
. This authorization shall be from the date of deliberation and approval by the general meeting of shareholders to the date of completion of the above authorization.
The board of directors of the company intends to authorize the chairman and the secretary of the board of directors to handle specific matters related to this issuance in accordance with the scope of authorization of the general meeting of shareholders.
voting result :__9__ votes in favor, __0__ votes against, __0__ abstentions.
This proposal still needs to be reviewed and approved by the company's shareholders' meeting.
4. "Proposal on Requiring the General Meeting of Shareholders of the Company to Authorize the Board of Directors to Take Repayment Safeguard Measures in Case of Expected Failure to Pay Bond Principal and Interest on Time or Failure to Pay Bond Principal and Interest on Time"
The Company Requested the General Meeting of Shareholders to Authorize the Board of Directors to Make the following Resolutions and Take Corresponding Measures :
1 , no distribution of profits to shareholders;
2 , suspending the implementation of capital expenditure projects such as major foreign investment, mergers and acquisitions;
3 , reduce or suspend the salaries and bonuses of directors and senior management personnel;
4 , the main responsible person shall not be transferred.
voting result :__9__ votes in favor, __0__ votes against, __0__ abstentions.
This proposal still needs to be reviewed and approved by the company's shareholders' meeting.
Proposal of 5. on Convening the First Extraordinary General Meeting of Shareholders in 2013
Decided to Convene the First Extraordinary General Meeting of Shareholders in 2013 on 1 March 22 (Tuesday) in 2013 , for details, please refer to the "Notice on Convening the First Extraordinary General Meeting of Shareholders in 2013 " published on the same day.
voting result :__9__ votes in favor, __0__ votes against, __0__ abstentions.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
December 31, 2012
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05